- Lonza and InduPro have entered into a licensing agreement under which InduPro will gain access to Lonza’s GlycoConnect®, HydraSpace®, and linker-payload technologies for the development of antibody-drug conjugates.
- The technologies will be used to support ADC programs targeting up to two oncology antigens, combining InduPro’s bispecific antibody platform with Lonza’s ADC capabilities.
Lonza and InduPro have entered into a licensing agreement to support the development of antibody-drug conjugate (ADC) therapies targeting cancer. Under the agreement, Lonza, through one of its affiliated companies, will grant InduPro a non-exclusive worldwide license to its GlycoConnect®, HydraSpace®, and linker-payload technologies for use in ADC programs targeting up to two oncology antigens.
The collaboration will combine InduPro’s proprietary bispecific antibody platform with Lonza’s ADC technologies, including GlycoConnect®, HydraSpace®, and SYNtecan E™. The companies said the technologies will be used to develop therapeutic approaches designed to address diseases such as cancer through targeted delivery and precision targeting mechanisms.
The agreement expands InduPro’s access to ADC development technologies while leveraging Lonza’s expertise in bioconjugation technologies and manufacturing. According to the companies, the collaboration is intended to support the advancement of next-generation ADC programs focused on oncology applications.
“We are pleased to be starting this collaboration with InduPro, which underscores the strength and versatility of our ADC platform.”
Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis, Lonza
InduPro stated that the agreement will support the development of its proximity-driven bispecific ADC pipeline by combining its disease-specific co-target discovery capabilities with Lonza’s ADC technology platform. The companies said the collaboration aims to develop differentiated therapeutic approaches for hard-to-treat tumors.
